LSV Asset Management Has $278.16 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• LSV Asset Management reduced its stake in United Therapeutics Corporation by 0.7%, owning 902,323 shares worth approximately $278 million after selling 6,401 shares in the first quarter.
• Several other institutional investors have also adjusted their holdings, with Allianz Asset Management increasing its stake by 96.9% during the same period.
• Despite a missed earnings estimate of $6.41 EPS versus the expected $6.80, United Therapeutics reported revenue growth of 11.7% compared to the prior year.

LSV Asset Management lowered its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 0.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 902,323 shares of the biotechnology company's stock after selling 6,401 shares during the period. LSV Asset Management owned about 2.00% of United Therapeutics worth $278,159,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. LPL Financial LLC grew its holdings in shares of United Therapeutics by 122.8% during the fourth quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock worth $5,024,000 after buying an additional 7,847 shares in the last quarter. Orion Portfolio Solutions LLC grew its holdings in shares of United Therapeutics by 22.4% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,021 shares of the biotechnology company's stock worth $1,419,000 after buying an additional 735 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in shares of United Therapeutics by 6.2% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company's stock worth $1,387,000 after buying an additional 228 shares in the last quarter. Geode Capital Management LLC increased its position in United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after purchasing an additional 44,277 shares during the last quarter. Finally, Westpac Banking Corp increased its position in United Therapeutics by 6.5% during the fourth quarter. Westpac Banking Corp now owns 1,249 shares of the biotechnology company's stock worth $441,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on UTHR shares. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the stock a "buy" rating in a research note on Thursday, July 31st. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Morgan Stanley cut their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Finally, Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $379.69.

United Therapeutics Price Performance

Shares of UTHR stock traded down $2.51 during trading hours on Wednesday, reaching $302.30. The stock had a trading volume of 376,612 shares, compared to its average volume of 515,291. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a 50-day simple moving average of $297.62 and a 200-day simple moving average of $312.36. The firm has a market capitalization of $13.64 billion, a PE ratio of 11.80, a price-to-earnings-growth ratio of 4.43 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.85 EPS. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 70,681 shares of company stock worth $21,318,359 in the last 90 days. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.